 ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A (apo(a)), a key component of lipoprotein(a) (Lp(a)), which has been genetically linked with increased risk of cardiovascular diseases. ARC-LPA employs Arrowhead's new hepatic delivery format being developed for subcutaneous administration. This program has not yet been designated by Arrowhead as entering pre-IND development. 